Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT

NCT01931150 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Cetuximab-induced Papulopustular (Acneiform) Rash Who Have
Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Topical Dapsone 5% Gel
OTHER: Moisturizer
DRUG: oral antibiotics

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]